Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCD101 in Healthy Adult Volunteers
NCT07282145Phase 1Completed
- Sponsor
- Bichedam
- Start
- Sep 2025
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BCD101 in essential hypertension (14 arms), sponsored by Bichedam. Primary endpoints: Number of Participants With Adverse Events, Physical Examination Abnormalities and 5 more. Started Sep 2025; status: completed.
02
Drugs
BCD101
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT07282145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07282145.